These findings highlight a novel role for extracellular HSPB5 in regulating neuroinflammation and suggest that targeting HSPB5-modulated neuroinflammation could be a potential therapeutic approach for MS (Guo et al., 2019). Here, CRYAB is linked to myeloid sarcoma.